echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Overview of the development of mRNA vaccines: part three

    Overview of the development of mRNA vaccines: part three

    • Last Update: 2021-09-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Part III: mRNA vaccination and its mechanism of triggering the immune response

     

    The location of the vaccination affects the induced immune response

    In addition to the vaccine component itself, the delivery method and location of the vaccine also affect its effectiveness (Figure 1)
    .


    The vaccine is usually injected into the muscle or subcutaneous fat tissue


     

    Figure 1 Immune response induced by mRNA injection in different parts

    The figure lists the advantages and disadvantages of the different methods
    .


    Generally speaking, APC directly transfected with mRNA is not a necessary prerequisite for effective induction of immune response


     

    Once the mRNA molecule is released from LNP into the cytoplasm, it is sensed by toll-like receptors (TLR) such as TLR3 or 7/8.
    Retinoic acid-inducing gene (RIG)-I is promoted by retinoic acid-inducing gene (RIG)-I, type I Interferon (IFN) is secreted into the extracellular matrix
    .


    Create an environment conducive to Th1 reaction rather than Th2 reaction


     

    Figure 2 The reaction of cells ingesting LNP-coated mRNA vaccine

     

    Figure 3 The effect of mRNA vaccine on immune function

    a) The influence of exogenous mRNA on innate immunity
    .


    Receptors such as TLR in endosomes and RIG-I and MDA5 in cytoplasm can detect exogenous mRNA


     

    Figure 4, Figure 5 and Figure 6 show how mRNA vaccines trigger natural immune responses
    .

     

    Figure 4 Exogenous mRNA triggers the innate immune response mechanism

     

    The mRNA vaccine synthesized by IVT can be recognized by PRR (including endosomal TLR3, -7, -8 and cytoplasmic innate immune receptors RIG-I and MDA5)
    .


    The dsRNA produced by inaccurate T7 polymerase activity is recognized by TLR8 and RIG-I, induces the expression of pro-inflammatory cytokines, and promotes 2'-5' -oligoadenylate synthase/RNase L and PKR-dependent eIF2α phosphorylation Mediated RNA degradation and translational inhibition


     

    Figure 5 mRNA in vitro transcription and innate immune activation

    (A) In vitro transcription of mRNA
    .


    In vitro mRNA transcript of DNA encoding the antigen with a sequence as a template, comprising a single-stranded RNA (ssRNA), double-stranded RNA (dsRNA) and the like


    (B) RNA translation and antigen presentation
    .


    mRNA enters the cytoplasm through endocytosis


    (C) Self-assisting effect
    .


    Various pattern recognition receptors (PRR) can recognize mRNA transcripts in vitro


    Figure 6 Innate immune induction of mRNA vaccine

    Dendritic cells (DC) have innate immunity to two mRNA vaccines
    .
    The RNA sensor is yellow, the antigen is red, the DC maturation factor is green, and the peptide-major histocompatibility complex (MHC) complex is light blue and red; an example of a lipid nanoparticle carrier is shown in the upper right corner
    .
    This figure shows a non-exhaustive list of the main known RNA receptors, which help to identify double-stranded and unmodified single-stranded RNA, select unmodified, unpurified (part a) and nucleoside modifications, and quickly Protein liquid chromatography (FPLC) purification (Part b) mRNA is used to illustrate two forms of mRNA vaccines, with and without known forms of mRNA sensing
    .
    The dashed arrow indicates a decrease in antigen expression
    .
    Term explanation: Ag, antigen; PKR, interferon-induced double-stranded RNA activated protein kinase; MDA5, interferon-induced helicase C domain protein 1 (also known as IFIH1); IFN, interferon; m1ψ, 1- Methyl pseudouridine; OAS, 2'-5'-oligoadenylate synthase; TLR, Toll-like receptor
    .

     

    Figure 7 shows the mechanism by which mRNA vaccine triggers the body's adaptive immune response
    .

     

    Figure 7 Adaptive immune response triggered by mRNA vaccination

     

    Local inflammation at the injection site promotes the infiltration of immune cells, including neutrophils, monocytes, myeloid dendritic cells (MDC) and plasmacytoid dendritic cells (PDC)
    .
    Neutrophils can absorb LNP efficiently, and monocytes and mdc can translate mRNA more efficiently
    .
    Type I interferon (IFN) is stimulated to secrete
    .
    The mRNA/LNP and protein antigens will diffuse, and the cells will migrate to the vaccine-draining lymph nodes
    .
    The presentation of antigens to T cells and the interaction of antigens with B cells all occur at these sites
    .
    This leads to the formation of a germinal center, which produces memory B cells that reside in the bone marrow and plasma cells that produce antibodies
    .

     

    Overview of the development of mRNA vaccines: part one

    Overview of the development of mRNA vaccines: part two

    Overview of the development of mRNA vaccines: part three

    Overview of the development of mRNA vaccines: part four

    Overview of the development of mRNA vaccines: Part 5

     

     

    (Source: Internet, for reference only)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.